1.

Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.

Koundinya M, Sudhalter J, Courjaud A, Lionne B, Touyer G, Bonnet L, Menguy I, Schreiber I, Perrault C, Vougier S, Benhamou B, Zhang B, He T, Gao Q, Gee P, Simard D, Castaldi MP, Tomlinson R, Reiling S, Barrague M, Newcombe R, Cao H, Wang Y, Sun F, Murtie J, Munson M, Yang E, Harper D, Bouaboula M, Pollard J, Grepin C, Garcia-Echeverria C, Cheng H, Adrian F, Winter C, Licht S, Cornella-Taracido I, Arrebola R, Morris A.

Cell Chem Biol. 2018 Jun 21;25(6):705-717.e11. doi: 10.1016/j.chembiol.2018.03.005. Epub 2018 Apr 5.

PMID:
29628435
2.

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.

Bonnevaux H, Lemaitre O, Vincent L, Levit MN, Windenberger F, Halley F, Delorme C, Lengauer C, Garcia-Echeverria C, Virone-Oddos A.

Mol Cancer Ther. 2016 Jul;15(7):1460-71. doi: 10.1158/1535-7163.MCT-15-0496. Epub 2016 May 12.

3.

Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry.

Munson M, Lieberman H, Tserlin E, Rocnik J, Ge J, Fitzgerald M, Patel V, Garcia-Echeverria C.

Drug Discov Today. 2015 Aug;20(8):978-87. doi: 10.1016/j.drudis.2015.03.010. Epub 2015 Mar 24. Review.

PMID:
25814036
4.

Anti-miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation.

Wagenaar TR, Zabludoff S, Ahn SM, Allerson C, Arlt H, Baffa R, Cao H, Davis S, Garcia-Echeverria C, Gaur R, Huang SM, Jiang L, Kim D, Metz-Weidmann C, Pavlicek A, Pollard J, Reeves J, Rocnik JL, Scheidler S, Shi C, Sun F, Tolstykh T, Weber W, Winter C, Yu E, Yu Q, Zheng G, Wiederschain D.

Mol Cancer Res. 2015 Jun;13(6):1009-21. doi: 10.1158/1541-7786.MCR-14-0703. Epub 2015 Mar 10.

5.

Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells.

Wagenaar TR, Tolstykh T, Shi C, Jiang L, Zhang J, Li Z, Yu Q, Qu H, Sun F, Cao H, Pollard J, Dai S, Gao Q, Zhang B, Arlt H, Cindhuchao M, Hoffmann D, Light M, Jensen K, Hopke J, Newcombe R, Garcia-Echeverria C, Winter C, Zabludoff S, Wiederschain D.

Nucleic Acids Res. 2015 Jan;43(2):1204-15. doi: 10.1093/nar/gku1367. Epub 2014 Dec 30.

6.

Antibody-drug conjugates—a new wave of cancer drugs.

Bouchard H, Viskov C, Garcia-Echeverria C.

Bioorg Med Chem Lett. 2014 Dec 1;24(23):5357-63. doi: 10.1016/j.bmcl.2014.10.021. Epub 2014 Oct 13. Review.

7.

Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.

Pasquier B, El-Ahmad Y, Filoche-Rommé B, Dureuil C, Fassy F, Abecassis PY, Mathieu M, Bertrand T, Benard T, Barrière C, El Batti S, Letallec JP, Sonnefraud V, Brollo M, Delbarre L, Loyau V, Pilorge F, Bertin L, Richepin P, Arigon J, Labrosse JR, Clément J, Durand F, Combet R, Perraut P, Leroy V, Gay F, Lefrançois D, Bretin F, Marquette JP, Michot N, Caron A, Castell C, Schio L, McCort G, Goulaouic H, Garcia-Echeverria C, Ronan B.

J Med Chem. 2015 Jan 8;58(1):376-400. doi: 10.1021/jm5013352. Epub 2014 Nov 26.

PMID:
25402320
8.

A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.

Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, Bachelot MF, Lamberton A, Mathieu M, Bertrand T, Marquette JP, El-Ahmad Y, Filoche-Romme B, Schio L, Garcia-Echeverria C, Goulaouic H, Pasquier B.

Nat Chem Biol. 2014 Dec;10(12):1013-9. doi: 10.1038/nchembio.1681. Epub 2014 Oct 19.

PMID:
25326666
9.

Developing second generation antibody-drug conjugates: the quest for new technologies.

Garcia-Echeverria C.

J Med Chem. 2014 Oct 9;57(19):7888-9. doi: 10.1021/jm501298k. Epub 2014 Sep 15.

PMID:
25220827
10.

PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.

Guo Z, Wang A, Zhang W, Levit M, Gao Q, Barberis C, Tabart M, Zhang J, Hoffmann D, Wiederschain D, Rocnik J, Sun F, Murtie J, Lengauer C, Gross S, Zhang B, Cheng H, Patel V, Schio L, Adrian F, Dorsch M, Garcia-Echeverria C, Huang SM.

Blood. 2014 Sep 11;124(11):1777-89. doi: 10.1182/blood-2014-01-551234. Epub 2014 Jul 8.

11.

Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance.

Huang SM, Wang A, Greco R, Li Z, Barberis C, Tabart M, Patel V, Schio L, Hurley R, Chen B, Cheng H, Lengauer C, Pollard J, Watters J, Garcia-Echeverria C, Wiederschain D, Adrian F, Zhang J.

Oncotarget. 2014 May 30;5(10):3362-74.

12.

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR.

Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7.

13.

Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitors.

Certal V, Halley F, Virone-Oddos A, Filoche-Rommé B, Carry JC, Gruss-Leleu F, Bertin L, Guizani H, Pilorge F, Richepin P, Karlsson A, Charrier V, Abecassis PY, Vincent L, Nicolas JP, Lengauer C, Garcia-Echeverria C, Schio L.

Bioorg Med Chem Lett. 2014 Mar 15;24(6):1506-10. doi: 10.1016/j.bmcl.2014.02.004. Epub 2014 Feb 8.

PMID:
24560540
14.

Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.

Certal V, Carry JC, Halley F, Virone-Oddos A, Thompson F, Filoche-Rommé B, El-Ahmad Y, Karlsson A, Charrier V, Delorme C, Rak A, Abecassis PY, Amara C, Vincent L, Bonnevaux H, Nicolas JP, Mathieu M, Bertrand T, Marquette JP, Michot N, Benard T, Perrin MA, Lemaitre O, Guerif S, Perron S, Monget S, Gruss-Leleu F, Doerflinger G, Guizani H, Brollo M, Delbarre L, Bertin L, Richepin P, Loyau V, Garcia-Echeverria C, Lengauer C, Schio L.

J Med Chem. 2014 Feb 13;57(3):903-20. doi: 10.1021/jm401642q. Epub 2014 Jan 15.

PMID:
24387221
15.

Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches.

Gao Q, Mechin I, Kothari N, Guo Z, Deng G, Haas K, McManus J, Hoffmann D, Wang A, Wiederschain D, Rocnik J, Czechtizky W, Chen X, McLean L, Arlt H, Harper D, Liu F, Majid T, Patel V, Lengauer C, Garcia-Echeverria C, Zhang B, Cheng H, Dorsch M, Huang SM.

J Biol Chem. 2013 Oct 18;288(42):30125-38. doi: 10.1074/jbc.M113.473348. Epub 2013 Sep 3.

16.

The drug annotations series.

Zablocki J, Garcia-Echeverria C.

J Med Chem. 2013 Sep 12;56(17):6541. doi: 10.1021/jm401297r. Epub 2013 Sep 3. No abstract available.

PMID:
24000804
17.

Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.

Carry JC, Garcia-Echeverria C.

Bioorg Med Chem Lett. 2013 May 1;23(9):2480-5. doi: 10.1016/j.bmcl.2013.03.034. Epub 2013 Mar 16.

18.

FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells.

Kim S, Dubrovska A, Salamone RJ, Walker JR, Grandinetti KB, Bonamy GM, Orth AP, Elliott J, Porta DG, Garcia-Echeverria C, Reddy VA.

PLoS One. 2013;8(1):e51671. doi: 10.1371/journal.pone.0051671. Epub 2013 Jan 2.

19.

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, Chen Z, Wilson CJ, Bordas V, Le Douget M, Gaither LA, Borawski J, Monahan JE, Venkatesan K, Brümmendorf T, Thomas DM, Garcia-Echeverria C, Hofmann F, Sellers WR, Graus-Porta D.

Cancer Discov. 2012 Dec;2(12):1118-33. doi: 10.1158/2159-8290.CD-12-0210. Epub 2012 Sep 20.

20.

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.

Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J, Romanet V, Henry C, Murakami M, Guthy DA, Sterker D, Bergling S, Wilson C, Brümmendorf T, Fritsch C, Garcia-Echeverria C, Sellers WR, Hofmann F, Maira SM.

Mol Cancer Ther. 2012 Aug;11(8):1747-57. doi: 10.1158/1535-7163.MCT-11-1021. Epub 2012 May 31.

21.

Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.

Zumsteg A, Caviezel C, Pisarsky L, Strittmatter K, García-Echeverría C, Hofmann F, Christofori G.

Mol Cancer Res. 2012 Jun;10(6):800-9. doi: 10.1158/1541-7786.MCR-11-0522. Epub 2012 May 4.

22.

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.

Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21.

23.

Blocking the mTOR pathway: a drug discovery perspective.

Garcia-Echeverria C.

Biochem Soc Trans. 2011 Apr;39(2):451-5. doi: 10.1042/BST0390451. Review.

PMID:
21428918
24.

Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.

Dubrovska A, Elliott J, Salamone RJ, Kim S, Aimone LJ, Walker JR, Watson J, Sauveur-Michel M, Garcia-Echeverria C, Cho CY, Reddy VA, Schultz PG.

Clin Cancer Res. 2010 Dec 1;16(23):5692-702. doi: 10.1158/1078-0432.CCR-10-1601.

25.

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, García-Echeverría C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M.

Sci Transl Med. 2010 Sep 29;2(51):51ra70. doi: 10.1126/scitranslmed.3001599.

26.

From the bench to the bed side: PI3K pathway inhibitors in clinical development.

Maira SM, Finan P, Garcia-Echeverria C.

Curr Top Microbiol Immunol. 2010;347:209-39. doi: 10.1007/82_2010_60. Review.

PMID:
20582534
27.

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

García-Echeverría C.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4308-12. doi: 10.1016/j.bmcl.2010.05.099. Epub 2010 Jun 1. Review.

PMID:
20561789
28.

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.

Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, García-Echeverría C, Bardeesy N, Sharpless NE, Hayes ND, Kim WY, Engelman JA, Wong KK.

Cancer Cell. 2010 Jun 15;17(6):547-59. doi: 10.1016/j.ccr.2010.04.026.

29.

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL.

J Clin Invest. 2010 Jul;120(7):2406-13. doi: 10.1172/JCI41680. Epub 2010 Jun 7.

30.

89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GA, Lub-de Hooge MN, Schröder CP, de Vries EG.

J Nucl Med. 2010 May;51(5):761-7. doi: 10.2967/jnumed.109.071043. Epub 2010 Apr 15.

31.

PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.

Hägerstrand D, Lindh MB, Peña C, Garcia-Echeverria C, Nistér M, Hofmann F, Ostman A.

Neuro Oncol. 2010 Sep;12(9):967-75. doi: 10.1093/neuonc/noq029. Epub 2010 Apr 8.

32.

Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.

Massey AJ, Schoepfer J, Brough PA, Brueggen J, Chène P, Drysdale MJ, Pfaar U, Radimerski T, Ruetz S, Schweitzer A, Wood M, Garcia-Echeverria C, Jensen MR.

Mol Cancer Ther. 2010 Apr;9(4):906-19. doi: 10.1158/1535-7163.MCT-10-0055. Epub 2010 Apr 6.

33.

Hsp90 inhibitors: clinical development and future opportunities in oncology therapy.

Gao Z, Garcia-Echeverria C, Jensen MR.

Curr Opin Drug Discov Devel. 2010 Mar;13(2):193-202. Review.

PMID:
20205053
34.

NVP-BEZ235 as a new therapeutic option for sarcomas.

Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K.

Clin Cancer Res. 2010 Jan 15;16(2):530-40. doi: 10.1158/1078-0432.CCR-09-0816. Epub 2010 Jan 12.

35.

High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.

Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Maira SM, García-Echeverría C, Scotlandi K, De Giovanni C, Lollini PL.

Eur J Cancer. 2010 Feb;46(3):659-68. doi: 10.1016/j.ejca.2009.11.018. Epub 2009 Dec 22.

PMID:
20031388
36.

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.

Kaiser M, Lamottke B, Mieth M, Jensen MR, Quadt C, Garcia-Echeverria C, Atadja P, Heider U, von Metzler I, Türkmen S, Sezer O.

Eur J Haematol. 2010 Apr;84(4):337-44. doi: 10.1111/j.1600-0609.2009.01403.x. Epub 2009 Dec 17.

PMID:
20028416
37.

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.

Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira SM.

Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22299-304. doi: 10.1073/pnas.0905152106. Epub 2009 Dec 10.

38.

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK, Engelman JA.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8. doi: 10.1073/pnas.0905056106. Epub 2009 Oct 22.

39.

Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.

Stühmer T, Chatterjee M, Grella E, Seggewiss R, Langer C, Müller S, Schoepfer J, Garcia-Echeverria C, Quadt C, Jensen MR, Einsele H, Bargou RC.

Br J Haematol. 2009 Nov;147(3):319-27. doi: 10.1111/j.1365-2141.2009.07852.x. Epub 2009 Aug 13.

PMID:
19686236
40.

Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.

Brough PA, Barril X, Borgognoni J, Chene P, Davies NG, Davis B, Drysdale MJ, Dymock B, Eccles SA, Garcia-Echeverria C, Fromont C, Hayes A, Hubbard RE, Jordan AM, Jensen MR, Massey A, Merrett A, Padfield A, Parsons R, Radimerski T, Raynaud FI, Robertson A, Roughley SD, Schoepfer J, Simmonite H, Sharp SY, Surgenor A, Valenti M, Walls S, Webb P, Wood M, Workman P, Wright L.

J Med Chem. 2009 Aug 13;52(15):4794-809. doi: 10.1021/jm900357y.

PMID:
19610616
41.

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.

Cancer Res. 2009 Jul 15;69(14):5835-42. doi: 10.1158/0008-5472.CAN-08-4285. Epub 2009 Jul 7.

42.

Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.

Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, Cmiljanovic V, Stauffer F, Garcia-Echeverria C, Giese B, Maira SM, Wymann MP.

Mol Cancer Res. 2009 Apr;7(4):601-13. doi: 10.1158/1541-7786.MCR-08-0366.

43.

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.

Cao P, Maira SM, García-Echeverría C, Hedley DW.

Br J Cancer. 2009 Apr 21;100(8):1267-76. doi: 10.1038/sj.bjc.6604995. Epub 2009 Mar 24.

44.

PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.

Brachmann S, Fritsch C, Maira SM, García-Echeverría C.

Curr Opin Cell Biol. 2009 Apr;21(2):194-8. doi: 10.1016/j.ceb.2008.12.011. Epub 2009 Feb 7. Review.

PMID:
19201591
45.

PI3K inhibitors for cancer treatment: where do we stand?

Maira SM, Stauffer F, Schnell C, García-Echeverría C.

Biochem Soc Trans. 2009 Feb;37(Pt 1):265-72. doi: 10.1042/BST0370265. Review.

PMID:
19143644
46.

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.

Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C, Schultz PG, Reddy VA.

Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73. doi: 10.1073/pnas.0810956106. Epub 2008 Dec 30.

47.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK.

Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.

48.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.

Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.

49.

Drug discovery approaches targeting the PI3K/Akt pathway in cancer.

Garcia-Echeverria C, Sellers WR.

Oncogene. 2008 Sep 18;27(41):5511-26. doi: 10.1038/onc.2008.246. Review.

PMID:
18794885
50.

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.

Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM.

Cancer Res. 2008 Aug 15;68(16):6598-607. doi: 10.1158/0008-5472.CAN-08-1044.

Supplemental Content

Loading ...
Support Center